• J Am Heart Assoc · Dec 2015

    Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community.

    • Matthew Nayor, Na Wang, Martin G Larson, Ramachandran S Vasan, Daniel Levy, and Jennifer E Ho.
    • National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA (M.N., M.G.L., R.S.V., D.L., J.E.H.) Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.N.).
    • J Am Heart Assoc. 2015 Dec 31; 5 (1).

    BackgroundCirculating Galectin-3 (Gal-3) concentrations are associated with an increased incidence of heart failure, atrial fibrillation, chronic kidney disease, and mortality. Recent evidence suggests that Gal-3 may also be an important modulator of cardiometabolic traits such as adiposity, insulin resistance, and hyperglycemia. We examined the associations of blood Gal-3 concentrations and cardiometabolic disease traits in the Framingham Heart Study.Methods And ResultsIn cross-sectional analyses of 2946 Framingham Heart Study participants (mean age 59 years, 55% women), higher Gal-3 concentrations were associated with higher body mass index, waist circumference, and triglycerides (P<0.0001 for all). Higher Gal-3 was associated with greater odds of obesity (multivariable-adjusted odds ratio 1.16 per 1-SD increase in log-Gal-3, 95% CI 1.06-1.28, P=0.002) and hypertension (odds ratio 1.18, 95% CI 1.07-1.29, P=0.0006). In prospective analyses, Gal-3 was associated with incident metabolic syndrome (hazard ratio 1.22, 95% CI 1.10-1.36, P=0.0002) and diabetes (hazard ratio 1.21, 95% CI 1.04-1.41, P=0.02), in age- and sex-adjusted, but not multivariable-adjusted models.ConclusionsIn this large, community-based sample, circulating Gal-3 was associated with abdominal adiposity, dyslipidemia, and hypertension in cross-sectional analyses, but Gal-3 did not predict incident cardiometabolic disease after adjusting for cardiometabolic risk factors. Future investigations should focus on further elucidating mechanisms linking Gal-3 with cardiometabolic disease and on assessing whether modulation of the Gal-3 pathway might have positive cardiometabolic effects.© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…